Single-group interventional study (n=48) assessing effects of personal psychedelic experience (MDMA, LSD, psilocybin) on therapists' therapeutic attitude and related capacities during SÄPT training.
TherPsySE follows physicians and psychotherapists participating in SÄPT training to evaluate risks and benefits of personal experience with substance-induced altered states (MDMA, LSD, psilocybin) for therapeutic attitude, empathy and cognitive flexibility.
Interventions include group and 1:1 dosing sessions: MDMA (2×100 mg), LSD (75 and 150 µg) and psilocybin (15 and 25 mg); several non-drug study days focus on role-taking and training exercises.
Therapist personal experience with MDMA, LSD and psilocybin during SÄPT training (group and 1:1 settings).
2 × 100 mg oral (group setting).
LSD 75 and 150 µg in 1:1 setting.
Psilocybin 15 and 25 mg (group setting).